The investigation of the 50% effective dose of dexmedetomidine in general anesthesia maintainance

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058005

Enrollment

Unknown

Registered

2022-03-26

Start date

2022-03-31

Completion date

Unknown

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Dexmedetomidine group:Dexmedetomidine anesthesia maintainance

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 18-65 years, ASA I-II, elective abdominal surgery.

Exclusion criteria

Exclusion criteria: 1. Anemia, hemoglobin 30kg/m^2; 3. Sinus delay (HR<50bpm) or high heart block (II degree type 2 or III degree), cardiac insufficiency, LVEF<50%; 4. Liver and kidney dysfunction, systemic or vital organ infection, long-term use of a receptor blocking drugs for blood pressure, long-term use of psychotropic drugs, antiepileptic drugs or analgesics; 5. Conversion to open surgery, or excessive intraoperative bleeding and the need for blood transfusion; 6. Drinking alcohol; 7. Have a history of allergy to anesthetic drugs used in this study.

Design outcomes

Primary

Measure	Time frame
The ED50 of dexmedetomidine for maintainance of genaral anesthesia;	—

Secondary

Measure	Time frame
Intraoperative awareness;Perioperative mini-mental state examination (MMSE) score;	—

Countries

China

Contacts

Public ContactNi Cheng

nicheng83@163.com+86 13681569807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026